ATTD-ASIA Clinical Innovation Award

ATTD-ASIA alongside Eli Lilly and Company are happy to present the ATTD-ASIA Clinical Innovation Award.

This award will acknowledge significant contributions to improving the clinical practice of type 2 diabetes management. The ATTD-ASIA Clinical Innovation Award will emphasize practical improvements in day-to-day patient care. The focus will be on recognizing initiatives that directly enhance patient outcomes in clinical settings, particularly for type 2 diabetes patients.

The award will comprise of both financial and travel assistance to
support the work of the winner and enable them to attend ATTD-ASIA.

Key Dates

• Submissions close: 30 August
• Shortlisting: Mid-September
• Winner informed: October
• Award at ATTD-ASIA: December

Eligibility

• Open to HCPs, researchers, or digital health innovators.
• Candidates should exhibit innovative, patient-centered approaches and
  a commitment to translating research into practical solutions that can be scaled globally.

Criteria for Selection

1. Patient-Centered Innovation: Practical, patient-focused interventions that enhance diabetes care.
2. Clinical Impact: Demonstrated improvement in clinical outcomes, such as HbA1c, treatment adherence, and quality of life.
3. Sustainability & Scalability: Solutions with potential for widespread adoption and lasting impact across healthcare systems.
4. Evidence & Merit: Backed by strong research, pilot studies, or real-world data demonstrating effectiveness in improving patient care.
5. Alignment with ATTD’s Vision: Reflects ATTD’s focus on advancing diabetes technology.